Dong-A to receive $17 million in royalties from Trius Therapeutics

Published: 2008-09-29 06:47:00

Updated: 2008-09-29 06:47:00

Trius Therapeutics, U.S. based pharmaceutical company, is to pay some $17 million in royalties for the development of Dong-A’s new second generation oral and IV oxazolidinone antibiotic (DA-7218), as Trius Therapeutics, Inc. announced on September 22 the initiation of Phase 2 testing for DA-7218....

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK